IP Library › Granted Patent US 12,370,192
Granted Patent B2
US 12,370,192 · App. 17/753,803 · Granted Jul 29, 2025

Azole-fused pyridazin-3(2H)-one derivatives

Inventors: Holger Monenschein (San Diego, CA); Sean Murphy (San Diego, CA); Scott Olsen (San Diego, CA); Natasha O'Rourke (San Diego, CA); Holly Reichard (San Diego, CA); Melinda Davis (San Diego, CA); Betty Lam (San Diego, CA)
Assignee: Takeda Pharmaceutical Company Limited
A61K31/5025C07D471/04C07B2200/05
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,370,192
App. No.
17/753,803
Granted
Jul 29, 2025
Kind
B2
Abstract

Disclosed are compounds of Formula (1) and pharmaceutically acceptable salts thereof, wherein α, β, n, R 4 , R 5 , R 6 , R 8 , R 9 , R 10 , R 11 , X 1 , X 2 , X 3 and X 7 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions comprising them, and to their use for treating diseases, disorders, and conditions associated with GPR139.

Claims (235)

1. A compound of Formula 1,

a tautomer thereof, or a pharmaceutically acceptable salt of the compound or tautomer, wherein:

α is a single bond, β is a double bond, X 1 is NR 1N , and either (i) X 2 is N and X 3 is CR 3C

or (ii) X 2 is CR 2 and X 3 is selected from N and CR 3C ; or

α is a double bond, β is a single bond, X 3 is NR 3N and either (i) X 1 is N and X 2 is CR 2 ; or

(ii) X 1 is CR 1 C and X 2 is selected from N and CR 2 ;

n is selected from 0 and 1;

R 1C , R 2 , R 3C and R 4 are each independently selected from

(a) hydrogen; and

(b) C 1-6 alkyl and C 3-8 cycloalkyl, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo;

R 1N and R 3N are each independently selected from C 1-6 alkyl, C 3-8 cycloalkyl and C 6-10 aryl, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo;

R 5 is selected from hydrogen and C 1-6 alkyl, and

R 6 is selected from C 1-6 alkyl and C 3-8 cycloalkyl; or

R 5 and R 6 , together with the nitrogen and carbon atoms to which they are each respectively attached, form a C 3-6 heterocyclic ring, the heterocyclic ring being monocyclic and having one ring atom which is a heteroatom;

X 7 is selected from N and CR 7 ;

R 7 is selected from

(a) hydrogen, halo, cyano, hydroxy and amino; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo;

R 8 and R 9 are each independently selected from

(a) hydrogen, halo, cyano, hydroxy and amino; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo; or

R 8 and R 9 , together with the carbon atoms to which they are attached, form a C 4-5 heterocyclic ring, the heterocyclic ring having one or two ring atoms that are heteroatoms, each of heteroatoms being independently selected from N, O and S;

R 10 and R 11 are each independently selected from

(a) hydrogen, halo, cyano, hydroxy and amino; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

2. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein α is a single bond, β is a double bond, X 1 is NR 1N , and either (i) X 2 is N and X 3 is CR 3C or (ii) X 2 is CR 2 and X 3 is selected from N and CR 3C .

3. The compound, tautomer or pharmaceutically acceptable salt of claim 2 , wherein R 1N is selected from C 1-4 alkyl, cyclopropyl and phenyl.

4. The compound, tautomer or pharmaceutically acceptable salt of claim 2 , wherein X 2 is N and X 3 is CR 3C .

5. The compound, tautomer or pharmaceutically acceptable salt of claim 2 , wherein R 3C is selected from hydrogen, C 1-4 alkyl and cyclopropyl.

6. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein α is a double bond, β is a single bond, X 3 is NR 3N and either (i) X 1 is N and X 2 is CR 2 or (ii) X 1 is CR 1 C and X 2 is selected from N and CR 2 .

7. The compound, tautomer or pharmaceutically acceptable salt of claim 6 , wherein R 3N is selected from C 1-4 alkyl and C 3-6 cycloalkyl.

8. The compound, tautomer or pharmaceutically acceptable salt of claim 6 , wherein X 1 is CR 1C and X 2 is selected from N and CR 2 .

9. The compound, tautomer or pharmaceutically acceptable salt of claim 6 , wherein X 1 is CR 1C and X 2 is N.

10. The compound, tautomer or pharmaceutically acceptable salt of claim 9 , wherein R 1C is selected from hydrogen, C 1-4 alkyl and cyclopropyl.

11. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 2 is hydrogen.

12. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 4 is selected from hydrogen, C 1-4 alkyl and cyclopropyl.

13. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 5 is hydrogen.

14. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein Re is methyl.

15. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein n is 0.

16. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein X 7 is CR 7 .

17. The compound, tautomer or pharmaceutically acceptable salt of claim 16 , wherein R 7 is selected from

(a) hydrogen and halo; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

18. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 8 is selected from

(a) hydrogen and halo; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

19. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 9 is selected from

(a) hydrogen and halo; and

(b) C 1-6 alkyl and C 1-6 alkoxy, each unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

20. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 10 is selected from hydrogen, halo and C 1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

21. The compound, tautomer or pharmaceutically acceptable salt of claim 1 , wherein R 11 is selected from hydrogen, halo and C 1-4 alkyl which is unsubstituted or substituted with 1 to 3 substituents independently selected from halo.

22. The compound of claim 1 , which is selected from the following compounds:

(S)-2-(4-methyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(4-methoxyphenyl)ethyl)-2-(4-methyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(4-isopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(4-isopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(4-methyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(4-methyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(4-isopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(4-isopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1-(tert-butyl)-4-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-N-(1-(3-fluoro-4-methoxyphenyl)ethyl)-2-(3-isopropyl-1,7-dimethyl-4-oxo-1H-pyrazolo[3,4-d]pyridazin-5 (4H)-yl) acetamide;

(S)-2-(1-(tert-butyl)-4-isopropyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-4-isopropyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-4-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-4-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-4-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-4-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methoxyphenyl)ethyl) acetamide;

(S)-N-(1-(p-tolyl)ethyl)-2-(1,3,4-trimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1-isopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(4-chloro-2-fluorophenyl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(3-fluorophenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2,5-dimethylphenyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2,3-difluorophenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxy-3-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

(S)-2-(1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(4-cyclopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(4-cyclopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(4-cyclopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(4-cyclopropyl-7-oxo-1-phenyl-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(3-isopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(3-isopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(3-isopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-isopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-isopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-isopropyl-3,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-isopropyl-3,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

(S)-2-(1-isopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

N-(1-(chroman-6-yl)ethyl)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-(3-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-N-(1-(4-chloro-2-methylphenyl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-mesitylethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-(2,4-dimethylphenyl)ethyl) acetamide;

(S)-N-(1-(2-chloro-4-fluorophenyl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl) acetamide;

(S)-N-(1-(4-chloro-2-methoxyphenyl) propan-2-yl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl) acetamide;

(S)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(3-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-mesitylethyl) acetamide;

(S)-N-(1-(2-chloro-4-fluorophenyl)ethyl)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-isopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-isopropyl-7-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

5-(2-(2-(4-chlorophenyl) pyrrolidin-1-yl)-2-oxoethyl)-3-cyclopropyl-1-methyl-1,5-dihydro-4H-pyrazolo[3,4-d]pyridazin-4-one;

6-(2-(2-(4-chlorophenyl) pyrrolidin-1-yl)-2-oxoethyl)-1-cyclopropyl-3-methyl-1,6-dihydro-7H-pyrazolo[3,4-d]pyridazin-7-one;

(S)-2-(1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

(S)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl)-2-(1,3,4-trimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1-isopropyl-3-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

N-(1-(chroman-6-yl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

2-(1-cyclopropyl-3,4-dimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl) acetamide;

2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2,3-dihydrobenzo[b][1,4]dioxin-6-yl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1,3,7-trimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl)-2-(1,3,7-trimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-N-(1-(p-tolyl)ethyl)-2-(1,3,7-trimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-N-(1-(4-(trifluoromethyl)phenyl)ethyl)-2-(1,3,7-trimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1,7-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(4-methoxyphenyl)ethyl)-2-(1,3,7-trimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-N-(1-(2,6-difluorophenyl)ethyl)-2-(1,3-dimethyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2-fluoro-4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2,4-difluorophenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(3-fluoro-4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(3-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-N-(1-(2-chloro-4-fluorophenyl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-fluoro-3-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(2,4,6-trifluorophenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-fluoro-3-methylphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(3,5-difluorophenyl)ethyl) acetamide;

(S)-N-(1-(2-chloro-6-fluorophenyl)ethyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1,7-dimethyl-4-oxo-1,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(5-(trifluoromethyl) pyridin-2-yl)ethyl) acetamide;

(S)-2-(3-methyl-4-oxo-3,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-methyl-4-oxo-3,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-methyl-4-oxo-1,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(1-methyl-4-oxo-1,4-dihydro-5H-imidazo[4,5-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethoxy)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-(4-methoxyphenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-phenylethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrrolo[2,3-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(3-fluorophenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(2-chloro-6-fluorophenyl)ethyl)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(3-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl)-N-(1-(2-fluoro-4-methylphenyl)ethyl) acetamide;

(S)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-phenylethyl) acetamide;

(S)-N-(1-(3-fluorophenyl)ethyl)-2-(1,3,4-trimethyl-7-oxo-1,7-dihydro-6H-pyrazolo[3,4-d]pyridazin-6-yl) acetamide;

(S)-2-(1-cyclobutyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-(bicyclo[1.1.1]pentan-1-yl)-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(1-(tert-butyl)-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-2-(3-cyclopropyl-1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(R)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-N-(1-(4-chlorophenyl)ethyl)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl) acetamide;

(S)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(4-methoxyphenyl)ethyl)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl) acetamide;

(S)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl) acetamide;

(S)-2-(1-isopropyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(methyl-d3)phenyl)ethyl) acetamide;

(S)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(methyl-d3)phenyl)ethyl) acetamide;

(S)-2-(1-isopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(methyl-d3)phenyl)ethyl) acetamide;

(S)-2-(1-methyl-4-oxo-3-(trifluoromethyl)-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(p-tolyl)ethyl) acetamide;

(S)-N-(1-(2-fluoro-4-methylphenyl)ethyl)-2-(1-methyl-4-oxo-3-(trifluoromethyl)-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-N-(1-(3-fluoro-4-methylphenyl)ethyl)-2-(1-methyl-4-oxo-3-(trifluoromethyl)-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-methyl-4-oxo-3-(trifluoromethyl)-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl)-N-(1-(4-(trifluoromethyl)phenyl)ethyl) acetamide;

(S)-N-(cyclopropyl (phenyl)methyl)-2-(1-cyclopropyl-3-methyl-4-oxo-1,4-dihydro-5H-pyrazolo[3,4-d]pyridazin-5-yl) acetamide;

(S)-2-(1-methyl-7-oxo-1,7-dihydro-6H-pyrrolo[2,3-d]pyridazin-6-yl)-N-(1-(4-(methyl-d3)phenyl)ethyl) acetamide;

a tautomer of any one of the aforementioned compounds, and a pharmaceutically acceptable salt of any one of the aforementioned compounds or tautomer thereof.

23. A pharmaceutical composition comprising:

a compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 ; and

a pharmaceutically acceptable excipient.

24. A compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 for use as a medicament.

25. A method for activating GPR139 in a subject in need thereof, the method comprising administering to the subject a compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 .

26. A method of reversing, alleviating, or inhibiting the progress of a disease, disorder or condition, or reversing, alleviating, or inhibiting the progress of one or more symptoms of such a disease, disorder or condition in a subject in need thereof, wherein the method comprises administering to the subject a compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 , wherein the disease, disorder or condition is associated with GPR139.

27. A method of reversing, alleviating, or inhibiting the progress of a disease, disorder or condition, or reversing, alleviating, or inhibiting the progress of one or more symptoms of such a disease, disorder or condition in a subject in need thereof, wherein the method comprises administering to the subject a compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 , wherein the disease, disorder or condition is selected from schizophrenia, autism spectrum disorder, sleep disorders, depression, bipolar disorder, cognitive impairment, attention deficit hyperactivity disorder, post-traumatic stress disorder, substance use disorder, substance abuse, drug addiction, eating disorders, obsessive compulsive disorder, anxiety disorders, epilepsy, pain, fibromyalgia, Alzheimer's disease and Parkinson's disease.

28. A combination comprising a compound, tautomer or pharmaceutically acceptable salt as defined in claim 1 , and at least one additional pharmacologically active agent.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2023
From: MONENSCHEIN, HOLGER; MURPHY, SEAN; OLSEN, SCOTT; O'ROURKE, NATASHA; REICHARD, HOLLY; DAVIS, MELINDA; LAM, BETTY
To: TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
Reel/Frame 063512/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 2, 2023
From: TAKEDA DEVELOPMENT CENTER AMERICAS, INC.
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 063512/0537 →
Continuity (2)
Provisional Application 62901052 · Sep 16, 2019
Related Publication 20230028114A1 · Jan 26, 2023
References Cited (165)
US 3794726A · Ariyan · 1974 [cited by applicant]
US 4959367A · King · 1990 [cited by applicant]
US 4959368A · Awaya et al. · 1990 [cited by applicant]
US 6106864A · Dolan et al. · 2000 [cited by applicant]
US 6894043B1 · Pirotte et al. · 2005 [cited by applicant]
US 7253164B2 · Molteni et al. · 2007 [cited by applicant]
US 7262190B2 · Desos et al. · 2007 [cited by applicant]
US 8642660B2 · Goldfarb · 2014 [cited by applicant]
US 9150591B2 · Kori et al. · 2015 [cited by applicant]
US 9499568B2 · Kori et al. · 2016 [cited by applicant]
US 9556130B2 · Hitchcock et al. · 2017 [cited by applicant]
US 9770450B2 · Hitchcock et al. · 2017 [cited by applicant]
US 9884875B2 · Kori et al. · 2018 [cited by applicant]
US 10159677B2 · Hitchcock et al. · 2018 [cited by applicant]
US 10561662B2 · Hitchcock et al. · 2020 [cited by applicant]
US 11173161B2 · Hitchcock et al. · 2021 [cited by applicant]
US 20040242571A1 · Gouliaev et al. · 2004 [cited by applicant]
US 20050065146A1 · Cordi et al. · 2005 [cited by applicant]
US 20050165008A1 · Francotte et al. · 2005 [cited by applicant]
US 20050165064A1 · Kajino et al. · 2005 [cited by applicant]
US 20060079696A1 · Masson et al. · 2006 [cited by applicant]
US 20060128697A1 · Desos et al. · 2006 [cited by applicant]
US 20070004709A1 · Francotte et al. · 2007 [cited by applicant]
US 20090163545A1 · Goldfarb · 2009 [cited by applicant]
US 20090281107A1 · Congy et al. · 2009 [cited by applicant]
US 20100009974A1 · Francotte et al. · 2010 [cited by applicant]
US 20100010090A1 · Dominguez-Manzanares · 2010 [cited by applicant]
US 20100240635A1 · Cordi et al. · 2010 [cited by applicant]
US 20110034451A1 · Heinelt et al. · 2011 [cited by applicant]
US 20110118236A1 · Mochizuki et al. · 2011 [cited by applicant]
US 20120142672A1 · Koike et al. · 2012 [cited by applicant]
US 20160145218A1 · Hitchcock et al. · 2016 [cited by applicant]
US 20230002318A1 · Ikeda et al. · 2023 [cited by applicant]
US 20230134307A1 · Ikeda et al. · 2023 [cited by applicant]
US 20230150934A1 · Ikeda et al. · 2023 [cited by applicant]
US 20230227416A1 · Bowlin et al. · 2023 [cited by applicant]
US 20230310441A1 · Arkilo et al. · 2023 [cited by applicant]
EP 1500658A1 · 2005 [cited by applicant]
JP 2085851 · 1990 [cited by applicant]
JP 437742 · 1992 [cited by applicant]
JP 4119890 · 1992 [cited by applicant]
JP 7137462 · 1995 [cited by applicant]
JP 2009119088A1 · 2009 [cited by applicant]
JP 2009248543 · 2009 [cited by applicant]
WO WO199111172A1 · 1991 [cited by applicant]
WO WO199402518A1 · 1994 [cited by applicant]
WO WO1998055148A1 · 1998 [cited by applicant]
WO WO1999042456A2 · 1999 [cited by applicant]
WO WO2001030330A2 · 2001 [cited by applicant]
WO WO2001032013A1 · 2001 [cited by applicant]
WO WO2001040210A1 · 2001 [cited by applicant]
WO WO2004022521A1 · 2004 [cited by applicant]
WO WO2004099217A1 · 2004 [cited by applicant]
WO WO2004108673A2 · 2004 [cited by applicant]
WO WO2007073303A2 · 2007 [cited by applicant]
WO WO2007075387A1 · 2007 [cited by applicant]
WO WO2007147208A1 · 2007 [cited by applicant]
WO WO2008018827A1 · 2008 [cited by applicant]
WO WO2008085682A2 · 2008 [cited by applicant]
WO WO2008089005A2 · 2008 [cited by applicant]
WO WO2008094556A3 · 2008 [cited by applicant]
WO WO2009004430A1 · 2009 [cited by applicant]
WO WO2009061699A1 · 2009 [cited by applicant]
WO WO2009147167A1 · 2009 [cited by applicant]
WO WO2010054067A1 · 2010 [cited by applicant]
WO WO2010083141A1 · 2010 [cited by applicant]
WO WO2010098495A1 · 2010 [cited by applicant]
WO WO2010106249A1 · 2010 [cited by applicant]
WO WO2010140339A1 · 2010 [cited by applicant]
WO WO2011036885A1 · 2011 [cited by applicant]
WO WO2011036889A1 · 2011 [cited by applicant]
WO WO2011138265A2 · 2011 [cited by applicant]
WO WO2012020848A1 · 2012 [cited by applicant]
WO WO2014152917A2 · 2014 [cited by applicant]
WO WO2016020786 · 2016 [cited by applicant]
WO WO2016081736A1 · 2016 [cited by applicant]
WO WO2020081999A1 · 2020 [cited by applicant]
WO WO2020097609A1 · 2020 [cited by applicant]
WO WO2020198710A1 · 2020 [cited by applicant]
WO WO2021055295 · 2021 [cited by applicant]
WO WO2021055326A1 · 2021 [cited by applicant]
WO WO2021094832A1 · 2021 [cited by applicant]
WO WO2021224680 · 2021 [cited by applicant]
WO WO2022058791 · 2022 [cited by applicant]
ZA 981019 · 1998 [cited by applicant]
“A Randomized, Double-Blind, Placebo Controlled, Two-Period Cross-Over, Proof of Activity Study to Evaluate the Effects of TAK-041 on Motivational Anhedonia as Add-On to Antipsychotics in Participants With Stable Schizo… [cited by applicant]
Kunugi et al., “TAK-137, an AMPA-R Potentiator with Little Agonistic Effect, Has a Wide Therapeutic Window,” Neuropsychopharmacology, vol. 44, No. 5, Sep. 12, 2018, pp. 961-970. [cited by applicant]
Almarsson and M. J. Zaworotko, Chem. Commun. (2004) 17:1889-1896. [cited by applicant]
Berge et al., J. Pharm. Sci. (1997) 66:1-19. [cited by applicant]
Bettler, et al., “Review: Neurotransmitter Receptors II AMPA and Kainate Receptors”, Neuropharmacology, vol. 34, pp. 123-139, 1995. [cited by applicant]
Boraei et al., “Design and Synthesis of New Phthalazin Based Derivatives as Potential EGFR Inhibitors for the Treatment of Hepatocellular Carcinoma”, Bioorganic Chemistry, vol. 85, Dec. 31, 2018, pp. 293-307. [cited by applicant]
Bowie, et al., “Ionotropic Glutamate Receptors & CNS Disorders”, CNS & Neurological Disorders—Drug Targets, vol. 7, pp. 129-143, 2008. [cited by applicant]
Burk, M. J. et al., “A Convenient Asymmetric Synthesis of Alpha-1-Arylalkylamines Through the Enantioselective Hydrogenation of Enamides,” Journal of the American Chemical Society, , vol. 118, Jan. 1, 1996, pp. 5142-514… [cited by applicant]
Caddy, C. et al., “Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy,” Therapeutic Advances in Psychopharmacology, vol. 4, p. 75-99, 2… [cited by applicant]
Carlson et al., “Neural Correlates of Rapid Antidepressant Response to Ketamine in Treatment-Resistant Unipolar Depression: A Preliminary Positron Emission Tomography Study,” Biol Psychiatry, 2013, 73(12):1213-1221. [cited by applicant]
Castellani et al., “Copy Number Variation Distribution in Six Monozygotic Twin Pairs Discordant for Schizophrenia,” Twin Research and Human Genetics Apr. 2014; 17(2):108-120. [cited by applicant]
Castellani et al., “Biological relevance of CNV calling methods using familial relatedness including monozygotic twins,” BMC Bioinformatics, 2014, 15:114 (eight pages). [cited by applicant]
Cecil Textbook of Medicine, edited by Bennet, J.C. and Plum F., 20 [cited by applicant]
Chabchoub, F. et al., “New Method for the Synthesis of Hydrazonates. Reaction of Primary Amines With N-1-Ethoycarbonyl Hydrazonates: Synthesis of 1,2,4-Triazol-5-Ones,” Journal De La Societe Chimique De Tunisie, vol. 4,… [cited by applicant]
‘Chemical Encyclopedia’, vol. 4, p. 499-501, scientific publishing house ‘The Great Russian Encyclopedia’, Moscow, 1995 (English Translation). [cited by applicant]
Cilibrizzi et al., “6-Methyl-2,4-Disubstituted Pyridazin-3-ones: A Novel Class of Small-Molecule Agonists for Formyl Peptide Receptors,” Journal of Medicinal Chemistry, vol. 52, Jul. 29, 2009, pp. 5044-5057. [cited by applicant]
Database CA [Online] Chemical Abstracts Service, Columbus, Ohio, US; Goldfarb, David Scott: “Method using lifespan-altering compounds for altering the lifespan of eukaryotic organisms, and screening for such compounds,”… [cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Aug. 24, 2008, XP002754167, retrieved from STN; Database accession No. 1043204-06-03 (eight pages). [cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Mar. 26, 2014, XP002754168, retrieved from STN; Database accession No. 1574302-61-6 (eighteen pages). [cited by applicant]
Database Registry [Online] Chemical Abstracts Service, Columbus, Ohio, US; Aug. 4, 2010, XP002754169, retrieved from STN; Database accession No. 1234906-37-6 (eighteen pages). [cited by applicant]
Database Registry [Online], “Benzenesulfonic acid, 3-[8-[5-[2,2-dioxido-7-(3-sulfophenyl)-8Hpyrazolo[5,1-c][1,2,4]thiadiazin-8-ylidene]-1,3-pentadien-1-yl]-2,2-dioxido-1H-pyrazolo[5,1-c][1,2,4]thiadiazin-7-yl]-”Chemical… [cited by applicant]
Dermer et al., Bio/Technology, 1994, 12:320. [cited by applicant]
Devonshire, Ian M. et al., “Effects of urethane anaesthesia on sensory processing in the rat barrel cortex revealed by combined optical imaging and electrophysiology,” European Journal of Neuroscience (Eur. J. Neurosci.… [cited by applicant]
Diethelm et al., “Amine-Selective Bioconjugation Using Arene Diazonium Salts,” [cited by applicant]
Dingledine, et al., “The Glutamate Receptor Ion Channels”, Pharmacological Reviews, vol. 51, No. 1, pp. 7-61, 1999. [cited by applicant]
Dvorak et al., “Identification and SAR of glycine benzamides as potent agonists for the GPR139 receptor,” [cited by applicant]
Ebejer et al., “Genome-Wide Association Study of Inattention and Hyperactivity-Impulsivity Measured as Quantitative Traits,” Twin Research and Human Genetics Apr. 2013; 16(2):560-574. [cited by applicant]
Farley S. et al., “Antidepressant-like effects of an AMPA Receptor Potentiator Under a Chronic Mild Stress Paradigm,” International Journal of Neuropsychopharmacology, Cambridge Univ. Press, Cambridge, vol. 13, No. 9, O… [cited by applicant]
Finnin and Morgan, J. Pharm. Sci. 88( 10):955-958 (1999). [cited by applicant]
Francotte, et al., “Synthesis and pharmacological evaluation of a second generation of pyridothiadiazine 1,1-dioxides acting as AMPA potentiators”, Bioorganic & Medicinal Chemistry, vol. 16, pp. 9948-9956, 2008. [cited by applicant]
Freshney et al., Culture of Animal Cells, A manual of Basic Technique, Alan R. Liss, Inc. 1983, New York (seven pages). [cited by applicant]
Greene and P. G. Wuts, Protecting Groups in Organic Chemistry (1999). [cited by applicant]
Hald, et el., “Distinct Structural Features of Cyclothiazide Are Responsible for Effects on Peak Current Amplitude and Desensitization Kinetics at iGluR2”, Journal of Molecular Biology, vol. 391, pp. 906-917, 2009. [cited by applicant]
Haleblian, J. Pharm. Sci. (1975) 64(8):1269-88. [cited by applicant]
Higuchi and V. Stella “Pro-drugs as Novel Delivery Systems,” ACS Symposium Series 14 (1975). [cited by applicant]
Hitchcock, Stephen A., “Structural Modifications that Alter the P-Glycoprotein Efflux Properties of Compounds,” [cited by applicant]
Howlett, D. et al., Inhibition of fibril formation in b-amyloid peptide by a novel series of benzofurans, Biochem. J. vol. 340 (1), p. 283-289, 1999. [cited by applicant]
Hu et al., “Identification of Surrogate Agonists and Antagonists for Orphan G-Protein-Coupled Receptor GPR139,” Journal of Biomolecular Screening, 2009, 14:789-797. [cited by applicant]
Hunter et al., Negative symptoms and psychosocial functioning in schizophrenia: Neglected but important targets for treatment. European Psychiatry, 27(6), 432-436. [cited by applicant]
Isberg et al., “Computer-Aided Discovery of Aromatic L-a-Amino Acids as Agonists of the Orphan G Protein-Coupled Receptor GPR139”, Journal of Chemical Information Modeling, 2014, vol. 54, pp. 1553-1557. [cited by applicant]
Kandiah, N. et al., “Cerebral white matter disease is independently associated with BPSD in Alzheimer's disease,” Journal of the Neurological Sciences (J. Neurol. Sci.) vol. 337, p. 162-166, 2014. [cited by applicant]
Kattimani, Pramod P. et al., “C 5-Alkyl-1,3,4-Oxadiazol-2-ones Undergo Dealkylation upon Nitrogen Insertion to Form 2H-1,2,4-Triazol-3-ones: Synthesis of 1,2,4-Triazol-3-one Hybrids with Triazolothiadiazoles and Triazol… [cited by applicant]
Kim Y, Cho HY, Ahn YJ, et al. “Effect of NMDA NR2B antagonist on neuropathic pain in two spinal cord injury models,” Pain, vol. 153, p. 1022-1029, 2012. [cited by applicant]
L'abbe, et al., “Synthesis of Fused Dihydro-1,2,4-thiadiazolimines from Cyano-substituted Azides and Acyl Isothiocyanates”, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry, vol.… [cited by applicant]
Liang and Chen, “Fast-dissolving intraoral drug delivery systems,” Expert Opinion in Therapeutic Patents (2001) 11(6):981-986. [cited by applicant]
Lieberman et al. (ed.), Pharmaceutical Dosage Forms: Tablets, vol. 1-3 (2d ed., 1990). [cited by applicant]
Asgharnejad et al., “M148. Pharmacokinetic and Pharmacodynamic Properties of the Investigational AMPA Receptor Positive Allosteric Modulator TAK-653 After Single and Multiple Rising Doses in Healthy Volunteers,” ACP 57 [cited by applicant]
Xu, et al., “Safety, Pharmacokinetics, and Pharmacodynamics of TAK-831, a Selective D-Amino Acid Oxidase Inhibitor, in Healthy Volunteers,” ACNP 57th Annual Meeting: Poster Session III (two pages). [cited by applicant]
Maidment, I. D. et al., “Efficacy of Memantine on Behavioral and Psychological Symptoms Related to Dementia: A Systematic Meta-Analysis,” The Annals of Pharmacotherapy (Ann. Pharmacother.) vol. 42, p. 32-38, 2007. [cited by applicant]
Malinow, et al., “AMPA Receptor Trafficking and Synaptic Plasticity”, Ann. Rev. Neurosci, vol. 25, pp. 103-126, 2002. [cited by applicant]
Matsuo et al., “Molecular cloning and characterization of a novel Gq-coupled orphan receptor GPRg1 exclusively expressed in the central nervous system,” Biochemical and Biophysical Research Communications 331 (2005) 363… [cited by applicant]
Morrow, et al., “Recent advances in positive allosteric modulators of the AMPA receptor”, Current Opinion in Drug Discovery and Development, vol. 9, pp. 571-579, 2006. [cited by applicant]
Nesaragi, Aravind R. et al., “Microwave assisted regioselective synthesis of quinoline appended triazoles as potent anti-tubercular and antifungal agents via copper (I) catalyzed cycloaddition,” Bioorganic & Medicinal C… [cited by applicant]
Nisenbaum Eric S. et al., “Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy,Glutamate-Based Therapeutics for Psychiatric Disorders,” Jan. 1, 2010, pp. 39-56. [cited by applicant]
O'Roak et al., “Exome sequencing in sporadic autism spectrum disorders identifies severe de novo mutations,” Nature Genetics Jun. 2011; 43(6):585-589. [cited by applicant]
Okuzumi, et al., “Efficient solid-phase synthesis of diverse 1,2,3-benzotriazin-4-ones using tert-butyl nitrite”, Tetrahedron Letters, 2003, vol. 44, pp. 5539-5542. [cited by applicant]
Peeters, M. et al., “Effects of Pan- and Subtype-Selective N-Methyl-D-aspartate Receptor Antagonists on Cortical Spreading Depression in the Rat: Therapeutic Potential for Migraine,” The Journal of Pharmacology and Expe… [cited by applicant]
“Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study,” <ClinicalTrialsgov>, Apr. 22, 2016. [cited by applicant]
Phillips, et al., “50-Alkyl-benzothiadiazides: A New Subgroup of AMPA Receptor Modulators with Improved Affinity”, Bioorganic & Medicinal Chemistry, vol. 10, pp. 1229-1248, 2002. [cited by applicant]
Preskorn et al., “An Innovative Design to Establish Proof of Concept of the Antidepressant Effects of the NR2B Subunit Selective N-Methyl-D-Aspartate Antagonist, CP-101,606, in Patients With Treatment- Refractory Major … [cited by applicant]
Reichard et al.: “Discovery of TAK-041: a Potent and Selective GPR139 Agonist Explored for the Treatment of Negative Symptoms Associated with Schizophrenia”, Journal of Medicinal Chemistry, vol. 64, No. 15, pp. 11527-11… [cited by applicant]
Sartorius et al., “Remission of Major Depression Under Deep Brain Stimulation of the Lateral Habenula in a Therapy-Refractory Patient,” Biol Psychiatry 2010 67: e9-e11. [cited by applicant]
Schiffer, Hans et al.: “The Selective GPR139 Agonist TAK041 Reverses Anhedonia and Social Interaction Deficits In Rodent Models Related To Negative Symptoms In Schizophrenia,” Abstract S180 in SIRS 2020 Abstracts. [cited by applicant]
Schiffer, Hans, et al., “The Selective GPR139 Agonist TAK-041 Reverses Anhedonia and Social Interaction Deficits in Rodent Models Related to Negative Symptoms in Schizophrenia,” poster (one page). [cited by applicant]
Schmidt et al., “Mass spectroscopy of natural products. 20-Quinazoline carboxylic acids 4-Comparative positive and negative ion mass spectroscopic studies of 3,4-dihydroquinazolin-4-on-3-ylalkanoic acids and 3,4-dihydro… [cited by applicant]
Shi, et al., “Discovery and SAR of a Series of Agonists at Orphan G Protein-Coupled Receptor 139” ACS Medicinal Chemistry Letters, Apr. 14, 2011, vol. 2, No. 4, pp. 303-306. [cited by applicant]
Smith et al., “Advances in functional and structural MR image analysis and implementation as FSL” In Neurolmage (vol. 23, pp. S208-S219). [cited by applicant]
Somagond et al., “Microwave-Assisted Synthesis of November Symmetric Bis-1,2,4-triazolin-3-ones as Potent Inhibitors of CYP51: An Antifungal Activity Study”, [cited by applicant]
Strauss et al., “A New Perspective on Anhedonia in Schizophrenia,” [cited by applicant]
Thompson et al., “7-Chloro-3-methyl-3 ,4-dihydro-2H-1,2,4-benzothiadiazine-S,S-dioxide (IDRA 21), a congener of aniracetam, potently abates pharmacologically induced cognitive impairments in patas monkeys”, Proc. Natl. … [cited by applicant]
Treadway et al., “Reconsidering Anhedonia in Depression: Lessons from Translational Neuroscience,” [cited by applicant]
Vaisburg et al., “(2-Amino-phenyl)-amides of-omega—substituted alkanoic acids as new histone deacetylase inhibitors,” Bioorganic & Medicinal Chemistry Letters, vol. 14, No. 1, Jan. 5, 2004, pp. 283-287. [cited by applicant]
Verma et al., “Current Status of Drug Delivery Technologies and Future Directions,” [cited by applicant]
Ward et al., “Recent Advances in the Discovery of Selective AMPA Receptor Positive Allosteric Modulators”, [cited by applicant]
Yang et al., “Ketamine blocks bursting in the lateral habenula to rapidly relieve depression,” [cited by applicant]
Anthony Bouillon, et al., “ [cited by applicant]
A. Boraei et al., “Design and Synthesis of New Phthalazin Based Derivatives as Potential EGFR Inhibitors for the Treatment of Hepatocellular Carcinoma”, Bioorganic Chemistry, vol. 85, Dec. 31, 2018 (Dec. 31, 2018), pp. … [cited by applicant]
A. Cilibrizzi et al., “6-Methyl-2,4-Disubstituted Pyridazin-3-ones: A Novel Class of Small-Molecule Agonists for Formyl Peptide Receptors,” Journal of Medicinal Chemistry, vol. 52, Jul. 29, 2009 (Jul. 29, 2009), pp. 504… [cited by applicant]
International Search Report for International Application No. PCT/US2020/050823, dated Nov. 2, 2020 (three pages). [cited by applicant]
Written Opinion for International Application No. PCT/US2020/050823 (five pages). [cited by applicant]